ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

WSJ BLOG/Health: FDA OKs New Treatment for Soft-Tissue Sarcoma Patients

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Jennifer Corbett Dooren Patients with soft-tissue sarcoma, a rare cancer that starts in the body's muscle or connective tissues, now have a new treatment option. The FDA late yesterday approved GlaxoSmithKline's drug Votrient for use in patients with soft-tissue sarcoma, Dow Jones Newswires reports. This is the first new treatment in decades for the cancer. The National Cancer Institute estimates 11,000 cases of soft tissue sarcoma are diagnosed each year in the U.S. Votrient, a tablet taken orally, is already on the U.S. market to treat advanced kidney cancer. It was approved to treat several subtypes of advanced soft-tissue sarcoma, after prior chemotherapy. Votrient's approval follows the March recommendation of an agency advisory panel that the drug's benefits outweighed its risks. Clinical data involving 369 patients showed the drug temporarily slowed tumor growth but it isn't clear if the drug prolongs lives. And the FDA notes that Votrient carries the agency's toughest warning on its label, telling patients and doctors about the potentially fatal liver damage. Patients should be monitored for liver function and treatment halt if liver function declines, the agency says. Separately Thursday, the FDA granted wider approval to Novartis's Afinitor to treat non-cancerous kidney tumors that don't require immediate surgery. Afinitor was first approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs fail. Afinitor was approved to treat kidney tumors that are caused by a rare genetic disease called tuberous sclerosis complex, or TSC, which affects about 40,000 Americans. -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Novartis (NVS)
DateTimeHeadline
08/27/201519:20:00FDA Approves New Amgen Cholesterol Drug
08/21/201509:26:00Correction to Glaxo Sells Rights to Auto-Immune Drug to Novartis
08/21/201509:19:00Glaxo Sells Rights to Auto-Immune Drug to Novartis -- Update
08/21/201506:20:00Glaxo Sells Drug Rights to Novartis
08/21/201506:04:00Glaxa Sells Rights to Auto-Immune Drug to Novartis
08/21/201502:19:00GSK to Sell Rights in Ofatumumab for Auto-Immune Indications...
08/20/201503:03:00Novartis Gets EU Approval For Skin Cancer Treatment Odomzo
08/10/201509:15:00Active Equities to Watch in the Healthcare Sector -- AstraZeneca...
07/29/201508:10:07GSK Posts Sharp Fall in Profit
07/29/201507:29:46Novartis Spins Off Three Pipeline Drugs Into New Company
07/22/201519:45:14ADRs End Lower; National Bank of Greece, Petrobras Trade Actively
07/21/201518:40:12ADRs End Mixed; Infosys Rises
07/21/201515:19:03Novartis Can Sell Copycat of Amgen's Neupogen in September, Court...
07/21/201502:42:34Novartis Pressured by Dollar Strength -- Update
07/21/201502:40:10Novartis Pressured by Dollar Strength
07/21/201502:27:09Novartis Pressured by Dollar Strength
07/21/201501:53:33Novartis Pressured by Dollar Strength
07/17/201509:00:55Novartis AG 2Q 2015 -- Forecast
07/14/201507:13:03Midyear Report Card: Grading My Biotech Predictions for 2015
07/12/201511:02:03$1.5 Trillion Reasons to Invest in These Companies

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad